Setmelanotide
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
Rhythm · Phase 3 · Completed · Enrollment 15
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Setmelanotide | n/r | 45.5% | n/r | n/r |
Not shown
Every selected arm is drawn.